PMID- 37383601
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230919
IS  - 1948-9358 (Print)
IS  - 1948-9358 (Electronic)
IS  - 1948-9358 (Linking)
VI  - 14
IP  - 6
DP  - 2023 Jun 15
TI  - Targeting epicardial adipose tissue: A potential therapeutic strategy for heart 
      failure with preserved ejection fraction with type 2 diabetes mellitus.
PG  - 724-740
LID - 10.4239/wjd.v14.i6.724 [doi]
AB  - Heart failure with preserved ejection fraction (HFpEF) is a heterogeneous 
      syndrome with various comorbidities, multiple cardiac and extracardiac 
      pathophysiologic abnormalities, and diverse phenotypic presentations. Since HFpEF 
      is a heterogeneous disease with different phenotypes, individualized treatment is 
      required. HFpEF with type 2 diabetes mellitus (T2DM) represents a specific 
      phenotype of HFpEF, with about 45%-50% of HFpEF patients suffering from T2DM. 
      Systemic inflammation associated with dysregulated glucose metabolism is a 
      critical pathological mechanism of HFpEF with T2DM, which is intimately related 
      to the expansion and dysfunction (inflammation and hypermetabolic activity) of 
      epicardial adipose tissue (EAT). EAT is well established as a very active 
      endocrine organ that can regulate the pathophysiological processes of HFpEF with 
      T2DM through the paracrine and endocrine mechanisms. Therefore, suppressing 
      abnormal EAT expansion may be a promising therapeutic strategy for HFpEF with 
      T2DM. Although there is no treatment specifically for EAT, lifestyle management, 
      bariatric surgery, and some pharmaceutical interventions (anti-cytokine drugs, 
      statins, proprotein convertase subtilisin/kexin type 9 inhibitors, metformin, 
      glucagon-like peptide-1 receptor agonists, and especially sodium-glucose 
      cotransporter-2 inhibitors) have been shown to attenuate the inflammatory 
      response or expansion of EAT. Importantly, these treatments may be beneficial in 
      improving the clinical symptoms or prognosis of patients with HFpEF. Accordingly, 
      well-designed randomized controlled trials are needed to validate the efficacy of 
      current therapies. In addition, more novel and effective therapies targeting EAT 
      are needed in the future.
CI  - (c)The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights 
      reserved.
FAU - Shi, Yu-Jiao
AU  - Shi YJ
AD  - Department of Cardiovascular Medicine, Xiyuan Hospital, Chinese Academy of 
      Traditional Chinese Medicine, Beijing 100091, China.
FAU - Dong, Guo-Ju
AU  - Dong GJ
AD  - Department of Cardiovascular Medicine, Xiyuan Hospital, Chinese Academy of 
      Traditional Chinese Medicine, Beijing 100091, China. 13691393589@163.com.
FAU - Guo, Ming
AU  - Guo M
AD  - Department of Cardiovascular Medicine, Xiyuan Hospital, Chinese Academy of 
      Traditional Chinese Medicine, Beijing 100091, China.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - World J Diabetes
JT  - World journal of diabetes
JID - 101547524
PMC - PMC10294070
OTO - NOTNLM
OT  - Anti-hyperglycemic drugs
OT  - Epicardial adipose tissue
OT  - Heart failure with preserved ejection fraction
OT  - Inflammation
OT  - Sodium-glucose cotransporter-2 inhibitors
OT  - Type 2 diabetes mellitus
COIS- Conflict-of-interest statement: There are no conflicts of interest associated 
      with the senior author or coauthor who contributed their efforts to this 
      manuscript.
EDAT- 2023/06/29 13:42
MHDA- 2023/06/29 13:43
PMCR- 2023/06/15
CRDT- 2023/06/29 11:53
PHST- 2022/12/28 00:00 [received]
PHST- 2023/02/10 00:00 [revised]
PHST- 2023/04/24 00:00 [accepted]
PHST- 2023/06/29 13:43 [medline]
PHST- 2023/06/29 13:42 [pubmed]
PHST- 2023/06/29 11:53 [entrez]
PHST- 2023/06/15 00:00 [pmc-release]
AID - 10.4239/wjd.v14.i6.724 [doi]
PST - ppublish
SO  - World J Diabetes. 2023 Jun 15;14(6):724-740. doi: 10.4239/wjd.v14.i6.724.